Cost-effectiveness of lung cancer screening by low-dose CT in China: a micro-simulation study

od Yihui Du, Yanju Li, Grigory Sidorenkov, Rozemarijn Vliegenthart, Marjolein A. Heuvelmans, Monique D. Dorrius, Harry J.M. Groen, Shiyuan Liu, Li Fan, Zhaoxiang Ye, Marcel J.W. Greuter, Geertruida H. de Bock
Izdano 2022-03-01

Genomic Aberrations in Crizotinib Resistant Lung Adenocarcinoma Samples Identified by Transcriptome Sequencing.

od Ali Saber, Anthonie J van der Wekken, Klaas Kok, M Martijn Terpstra, Lisette J Bosman, Mirjam F Mastik, Wim Timens, Ed Schuuring, T Jeroen N Hiltermann, Harry J M Groen, Anke van den Berg
Izdano 2016-01-01

Clinical Outcomes With Dabrafenib Plus Trametinib in a Clinical Trial Versus Real-World Standard of Care in Patients With BRAF-Mutated Advanced NSCLC

od Bruce E. Johnson, MD, Christina S. Baik, MD, Julien Mazieres, MD, Harry J.M. Groen, MD, Barbara Melosky, MD, Jürgen Wolf, MD, Fatemeh Asad Zadeh Vosta Kolaei, PhD, Wen-Hsing Wu, MS, Stefanie Knoll, PhD, Meryem Ktiouet Dawson, MD, Adam Johns, PhD, David Planchard, MD
Izdano 2022-05-01

Common and rare EGFR and KRAS mutations in a Dutch non-small-cell lung cancer population and their clinical outcome.

od Gerald S M A Kerner, Ed Schuuring, Johanna Sietsma, Thijo J N Hiltermann, Remge M Pieterman, Gerard P J de Leede, John W G van Putten, Jeroen Liesker, Tineke E J Renkema, Peter van Hengel, Inge Platteel, Wim Timens, Harry J M Groen, CTMM Air Force Consortium
Izdano 2013-01-01